A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2018
At a glance
- Drugs IMG 7289 (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Imago BioSciences
- 08 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 08 Aug 2018 Planned primary completion date changed from 1 Feb 2018 to 31 Dec 2018.
- 01 Feb 2018 According to an Imago BioSciences media release, the company is planning to expand this trial in United States in 2018.